1Radiology, Children's Hospital of Chongqing Medical University, Chongqing, China
2GE Healthcare, MR Research China, Beijing, China
Presenting Author: Haoru Wang
Synopsis
Motivation:
Goals:
Approach:
Results:
Full abstract & presentation
The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.
Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.
To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.
1. Irwin, M.S.; Goldsmith, K.C. Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma. Journal of the National Comprehensive Cancer Network : JNCCN 2024, 22, doi:10.6004/jnccn.2024.7051. [doi]
2. Horwacik, I. The Extracellular Matrix and Neuroblastoma Cell Communication-A Complex Interplay and Its Therapeutic Implications. Cells 2022, 11, doi:10.3390/cells11193172. [doi]
3. Tadeo, I.; Berbegall, A.P.; Castel, V.; García-Miguel, P.; Callaghan, R.; Påhlman, S.; Navarro, S.; Noguera, R. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. British journal of cancer 2016, 115, 480-489, doi:10.1038/bjc.2016.210. [doi]
4. Wang, H.; Cai, J. Quantitative MRI in Childhood Neuroblastoma: Beyond the Assessment of Image-defined Risk Factors. Radiology. Imaging cancer 2024, 6, e240089, doi:10.1148/rycan.240089. [doi]
5. Jamin, Y.; Tucker, E.R.; Poon, E.; Popov, S.; Vaughan, L.; Boult, J.K.; Webber, H.; Hallsworth, A.; Baker, L.C.; Jones, C.; et al. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology 2013, 266, 130-140, doi:10.1148/radiol.12120128. [doi]